Log in
NASDAQ:BYSI

BeyondSpring Stock Forecast, Price & News

$14.83
+0.71 (+5.03 %)
(As of 10/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$13.72
Now: $14.83
$15.50
50-Day Range
$11.80
MA: $14.02
$15.62
52-Week Range
$9.38
Now: $14.83
$21.50
Volume189,722 shs
Average Volume63,160 shs
Market Capitalization$446.53 million
P/E RatioN/A
Dividend YieldN/A
Beta0.96
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development and commercialization of immuno-oncology cancer therapies. The company's lead asset is the Plinabulin that is in late stage clinical trials as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC) for the prevention of high and intermediate risk chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a programmed cell death protein 1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody to treat small cell lung cancer; and death protein 1 or programmed death-ligand 1, an antibodies and radiation or chemotherapy for the treatment of multiple cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform using ubiquitin mediated protein degradation pathway. BeyondSpring Inc. has collaboration agreements with the Fred Hutchinson Cancer Research Center and the University of Washington. The company was founded in 2010 and is headquartered in New York, New York.
Read More
BeyondSpring logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.22 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BYSI
CUSIPN/A
Phone1-646-305-6387
Employees61

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.12 per share

Profitability

Net Income$-38,080,000.00

Miscellaneous

Market Cap$446.53 million
Next Earnings Date12/16/2020 (Estimated)
OptionableNot Optionable
$14.83
+0.71 (+5.03 %)
(As of 10/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BYSI News and Ratings via Email

Sign-up to receive the latest news and ratings for BYSI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











BeyondSpring (NASDAQ:BYSI) Frequently Asked Questions

How has BeyondSpring's stock been impacted by COVID-19 (Coronavirus)?

BeyondSpring's stock was trading at $11.35 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BYSI shares have increased by 30.7% and is now trading at $14.83.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of BeyondSpring?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BeyondSpring in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for BeyondSpring
.

When is BeyondSpring's next earnings date?

BeyondSpring is scheduled to release its next quarterly earnings announcement on Wednesday, December 16th 2020.
View our earnings forecast for BeyondSpring
.

How were BeyondSpring's earnings last quarter?

BeyondSpring Inc. (NASDAQ:BYSI) posted its quarterly earnings data on Thursday, September, 3rd. The company reported ($0.46) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.57) by $0.11.
View BeyondSpring's earnings history
.

What price target have analysts set for BYSI?

4 Wall Street analysts have issued 12-month price objectives for BeyondSpring's shares. Their forecasts range from $25.00 to $46.00. On average, they expect BeyondSpring's share price to reach $35.00 in the next year. This suggests a possible upside of 136.0% from the stock's current price.
View analysts' price targets for BeyondSpring
.

Who are some of BeyondSpring's key competitors?

What other stocks do shareholders of BeyondSpring own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BeyondSpring investors own include Exelixis (EXEL), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Enterprise Products Partners (EPD), Johnson & Johnson (JNJ), Pfizer (PFE), Atara Biotherapeutics (ATRA), CorMedix (CRMD) and Dynavax Technologies (DVAX).

Who are BeyondSpring's key executives?

BeyondSpring's management team includes the following people:
  • Dr. Lan Huang, Co-Founder, Chairman & CEO (Age 49)
  • Ms. Elizabeth Adkins Czerepak, Chief Financial Officer (Age 64)
  • Mr. Richard J. Daly M.B.A., Chief Operating Officer (Age 59)
  • Dr. James R. Tonra Ph.D., Chief Scientific Officer (Age 54)
  • Stephen Kilmer, Head of Investor Relations

When did BeyondSpring IPO?

(BYSI) raised $4 million in an initial public offering on Thursday, March 9th 2017. The company issued 200,000 shares at $20.00 per share. Rodman & Renshaw (a Unit of H.C. Wainwright & Co.) acted as the underwriter for the IPO.

What is BeyondSpring's stock symbol?

BeyondSpring trades on the NASDAQ under the ticker symbol "BYSI."

How do I buy shares of BeyondSpring?

Shares of BYSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BeyondSpring's stock price today?

One share of BYSI stock can currently be purchased for approximately $14.83.

How big of a company is BeyondSpring?

BeyondSpring has a market capitalization of $446.53 million. The company earns $-38,080,000.00 in net income (profit) each year or ($1.55) on an earnings per share basis. BeyondSpring employs 61 workers across the globe.

What is BeyondSpring's official website?

The official website for BeyondSpring is www.beyondspringpharma.com.

How can I contact BeyondSpring?

BeyondSpring's mailing address is 28 LIBERTY STREET 39TH FLOOR, NEW YORK NY, 10005. The company can be reached via phone at 1-646-305-6387 or via email at [email protected]

This page was last updated on 10/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.